Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Anti-diabetic drugs
Imeglimin
Другие языки:

Imeglimin

Подписчиков: 0, рейтинг: 0
Imeglimin
Imeglimin.svg
Clinical data
Trade names Twymeeg
ATC code
Legal status
Legal status
  • Rx-only in Japan
Identifiers
  • (2S)-N6,N6,2-Trimethyl-1,2-dihydro-1,3,5-triazine-4,6-diamine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C6H13N5
Molar mass 155.205 g·mol−1
3D model (JSmol)
  • C[C@H]1NC(=NC(=N1)N)N(C)C
  • InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
  • Key:GFICWFZTBXUVIG-SCSAIBSYSA-N

Imeglimin (brand name Twymeeg) is an oral anti-diabetic medication. It was approved for use in Japan in June 2021.

It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion. It is the first approved drug of this class of anti-diabetic medication.


Новое сообщение